JP2009543783A5 - - Google Patents

Download PDF

Info

Publication number
JP2009543783A5
JP2009543783A5 JP2009519541A JP2009519541A JP2009543783A5 JP 2009543783 A5 JP2009543783 A5 JP 2009543783A5 JP 2009519541 A JP2009519541 A JP 2009519541A JP 2009519541 A JP2009519541 A JP 2009519541A JP 2009543783 A5 JP2009543783 A5 JP 2009543783A5
Authority
JP
Japan
Prior art keywords
substituted
alkynyl
alkoxy
alkenyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009519541A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009543783A (ja
JP6125741B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/015966 external-priority patent/WO2008008476A2/en
Publication of JP2009543783A publication Critical patent/JP2009543783A/ja
Publication of JP2009543783A5 publication Critical patent/JP2009543783A5/ja
Application granted granted Critical
Publication of JP6125741B2 publication Critical patent/JP6125741B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009519541A 2006-07-12 2007-07-11 可逆的なホスホトリエステル電荷中和保護基による核酸の形質導入可能な送達 Active JP6125741B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83057206P 2006-07-12 2006-07-12
US60/830,572 2006-07-12
PCT/US2007/015966 WO2008008476A2 (en) 2006-07-12 2007-07-11 Transducible delivery of nucleic acids by reversible phosphotriester charge neutralization protecting groups

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014217097A Division JP2015062421A (ja) 2006-07-12 2014-10-24 可逆的なホスホトリエステル電荷中和保護基による核酸の形質導入可能な送達

Publications (3)

Publication Number Publication Date
JP2009543783A JP2009543783A (ja) 2009-12-10
JP2009543783A5 true JP2009543783A5 (enExample) 2010-07-08
JP6125741B2 JP6125741B2 (ja) 2017-05-17

Family

ID=38923923

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009519541A Active JP6125741B2 (ja) 2006-07-12 2007-07-11 可逆的なホスホトリエステル電荷中和保護基による核酸の形質導入可能な送達
JP2014217097A Pending JP2015062421A (ja) 2006-07-12 2014-10-24 可逆的なホスホトリエステル電荷中和保護基による核酸の形質導入可能な送達

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014217097A Pending JP2015062421A (ja) 2006-07-12 2014-10-24 可逆的なホスホトリエステル電荷中和保護基による核酸の形質導入可能な送達

Country Status (7)

Country Link
US (1) US20090093425A1 (enExample)
EP (1) EP2046964B1 (enExample)
JP (2) JP6125741B2 (enExample)
CN (1) CN101506368B (enExample)
AU (1) AU2007272906B2 (enExample)
CA (1) CA2659103C (enExample)
WO (1) WO2008008476A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2638915A1 (en) 2006-02-10 2007-08-23 The Regents Of The University Of California Transducible delivery of sirna by dsrna binding domain fusions to ptd/cpps
US10022454B2 (en) 2008-09-23 2018-07-17 Liposciences, Llc Functionalized phosphorodiamites for therapeutic oligonucleotide synthesis
EP2346883B1 (en) * 2008-09-23 2016-03-23 Scott G. Petersen Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
RU2015151857A (ru) 2008-12-02 2019-01-15 Уэйв Лайф Сайенсес Джапан, Инк. Способ синтеза модифицированных по атому фосфора нуклеиновых кислот
WO2010129853A2 (en) * 2009-05-07 2010-11-11 The Regents Of The University Of California TRANSDUCIBLE DELIVERY OF NUCLEIC ACIDS USING MODIFIED dsRNA BINDING DOMAINS
EP2438079A4 (en) * 2009-06-01 2013-05-22 Univ California NUCLEIC ACID DELIVERY COMPOSITIONS AND METHOD OF USE THEREOF
MX342945B (es) 2009-07-06 2016-10-18 Ontorii Inc * Profármacos de ácido nucleico novedosos y métodos de uso de los mismos.
EP3252068B1 (en) 2009-10-12 2025-07-02 Larry J. Smith Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
WO2011109677A2 (en) * 2010-03-04 2011-09-09 University Of Louisville Research Foundation, Inc. Methods of increasing macropinocytosis in cancer cells
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
WO2012138846A2 (en) * 2011-04-05 2012-10-11 The Regents Of The University Of California Method and compositions comprising small rna agonist and antagonists to modulate inflammation
EP3248982A1 (en) 2011-07-19 2017-11-29 Wave Life Sciences Ltd. Thiosulfonate reagents for the synthesis of functionalized nucleic acids
JP5435016B2 (ja) 2011-12-01 2014-03-05 株式会社デンソー 半導体装置の製造方法
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
CA2879066C (en) 2012-07-13 2019-08-13 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
CA2879023C (en) 2012-07-13 2017-03-28 Wave Life Sciences Japan Asymmetric auxiliary group
CN104661664B (zh) 2012-07-13 2020-07-03 波涛生命科学有限公司 手性控制
CA2880869A1 (en) 2012-08-20 2014-02-27 The Regents Of The University Of California Polynucleotides having bioreversible groups
CA2880290C (en) 2012-09-12 2020-10-27 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide molecules targeting p53 and methods of use thereof
ES2704855T3 (es) 2012-09-12 2019-03-20 Quark Pharmaceuticals Inc Moléculas de oligonucleótido de doble cadena para p53 y métodos de uso de las mismas
AU2013356386B2 (en) * 2012-12-06 2017-09-07 Merck Sharp & Dohme Corp. Nucleoside kinase bypass compositions and methods
EP2928877B1 (en) * 2012-12-06 2020-01-22 Merck Sharp & Dohme Corp. Disulfide masked prodrug compositions and methods
CA2907184C (en) 2013-03-15 2022-12-06 Sutter West Bay Hospitals Falz for use as a target for therapies to treat cancer
US20160208247A1 (en) 2013-07-31 2016-07-21 Qbi Enterprises Ltd. Methods of use of sphingolipid polyalkylamine oligonucleotide compounds
EP3027222A1 (en) 2013-07-31 2016-06-08 QBI Enterprises Ltd. Sphingolipid-polyalkylamine-oligonucleotide compounds
CA2922698C (en) * 2013-08-29 2023-01-03 City Of Hope Cell penetrating conjugates comprising non-cell penetrating antibodies covalently attached to one or more phosphorothioate nucleic acids
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
MX2016009290A (es) 2014-01-16 2017-02-28 Wave Life Sciences Ltd Diseño quiral.
GB201410507D0 (en) * 2014-06-12 2014-07-30 Univ Bath Drug delivery enhancement agents
KR20190058477A (ko) 2016-08-17 2019-05-29 솔스티스 바이올로직스, 리미티드 폴리뉴클레오티드 구축물
WO2019006455A1 (en) 2017-06-30 2019-01-03 Solstice Biologics, Ltd. AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF
JP7282379B2 (ja) * 2017-08-22 2023-05-29 国立大学法人東海国立大学機構 修飾ポリヌクレオチド
US11510939B1 (en) 2019-04-19 2022-11-29 Apellis Pharmaceuticals, Inc. RNAs for complement inhibition

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
US6316003B1 (en) * 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US5674980A (en) * 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
WO1991014696A1 (en) * 1990-03-29 1991-10-03 Gilead Sciences, Inc. Oligonucleotide-transport agent disulfide conjugates
US5733523A (en) * 1990-12-10 1998-03-31 Akzo Nobel N.V. Targeted delivery of a therapeutic entity using complementary oligonucleotides
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5955591A (en) * 1993-05-12 1999-09-21 Imbach; Jean-Louis Phosphotriester oligonucleotides, amidites and method of preparation
US6051429A (en) * 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US6017700A (en) * 1995-08-04 2000-01-25 Bayer Corporation Cationic oligonucleotides, and related methods of synthesis and use
US6251433B1 (en) * 1996-08-13 2001-06-26 Chiron Corporation Polycationic polymers
WO1999029721A1 (en) * 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
US6531590B1 (en) * 1998-04-24 2003-03-11 Isis Pharmaceuticals, Inc. Processes for the synthesis of oligonucleotide compounds
US6903077B1 (en) * 1999-01-04 2005-06-07 University Of Vermont And State Agricultural College Methods and products for delivering nucleic acids
US20070026394A1 (en) * 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
US7491805B2 (en) * 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US6841535B2 (en) * 2000-07-31 2005-01-11 Active Motif Peptide-mediated transfection agents and methods of use
EP1345956A2 (en) * 2000-10-13 2003-09-24 University of Lausanne Intracellular delivery of biological effectors by novel transporter peptide sequences
US20040204377A1 (en) * 2002-11-26 2004-10-14 University Of Massachusetts Delivery of siRNAs
US20060178297A1 (en) * 2003-01-28 2006-08-10 Troy Carol M Systems and methods for silencing expression of a gene in a cell and uses thereof
US20040147027A1 (en) * 2003-01-28 2004-07-29 Troy Carol M. Complex for facilitating delivery of dsRNA into a cell and uses thereof
US7166692B2 (en) * 2003-03-04 2007-01-23 Canbrex Bio Science Walkersville, Inc. Intracellular delivery of small molecules, proteins, and nucleic acids
EP1631676A4 (en) * 2003-06-10 2006-12-20 Toolgen Inc TRANSDUCIBLE DNA BINDING PROTEINS
AU2004316996A1 (en) * 2003-06-20 2005-09-15 The Regents Of The University Of California Polypeptide transduction and fusogenic peptides
WO2005003315A2 (en) * 2003-07-01 2005-01-13 Allele Biotechnology & Pharmaceuticals, Inc. Compositions and methods for peptide-assisted transfection
JP4838722B2 (ja) * 2003-10-24 2011-12-14 ゲンシア コーポレーション ポリヌクレオチドを送達する方法、及び送達用組成物
US7514530B2 (en) * 2004-04-26 2009-04-07 Centre National De La Recherche Scientifique Peptide carrier for delivering siRNA into mammalian cells
CA2565685A1 (en) * 2004-05-04 2005-12-15 Nastech Pharmaceutical Company Inc. Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
US20060040882A1 (en) * 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
US20060035815A1 (en) * 2004-05-04 2006-02-16 Nastech Pharmaceutical Company Inc. Pharmaceutical compositions for delivery of ribonucleic acid to a cell
US20060030003A1 (en) * 2004-05-12 2006-02-09 Simon Michael R Composition and method for introduction of RNA interference sequences into targeted cells and tissues
US20050288246A1 (en) * 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
US7084248B2 (en) * 2004-07-14 2006-08-01 Gene Tools, Llc Peptide composition and method for delivering substances into the cytosol of cells
CA2574200A1 (en) * 2004-07-21 2006-01-26 Xiao Huang Hybrid wicking materials for use in high performance heat pipes
EP1789447B1 (en) * 2004-08-16 2012-04-25 Immune Disease Institute, Inc. Method of delivering rna interference and uses thereof
US20080027025A1 (en) * 2004-08-27 2008-01-31 The Regents Of The University Of California Protection From And Treatment Of Prion Protein Infection
US20090098049A1 (en) * 2004-09-07 2009-04-16 The Regents Of The University Of California Targeting transducible molecules to specific cell types
CA2638915A1 (en) * 2006-02-10 2007-08-23 The Regents Of The University Of California Transducible delivery of sirna by dsrna binding domain fusions to ptd/cpps
CN101421301A (zh) * 2006-02-10 2009-04-29 加利福尼亚大学董事会 通过dsRNA结合域与PTD/CPPS的融合物转导运输siRNA
EP2438079A4 (en) * 2009-06-01 2013-05-22 Univ California NUCLEIC ACID DELIVERY COMPOSITIONS AND METHOD OF USE THEREOF

Similar Documents

Publication Publication Date Title
JP2009543783A5 (enExample)
JP6884250B2 (ja) ペプチドオリゴヌクレオチドコンジュゲート
JP7008056B2 (ja) 修飾されたサブユニット間結合および／または末端基を有するオリゴヌクレオチドアナログ
AU2013306006B2 (en) Polynucleotides having bioreversible groups
CA2950960A1 (en) Polynucleotide constructs having bioreversible and non-bioreversible groups
US20160257961A1 (en) Polynucleotide constructs having disulfide groups
JP6954843B2 (ja) ペプチドオリゴヌクレオチドコンジュゲート
JP6496549B2 (ja) 脊髄性筋萎縮症における誘発されたエクソン包含
CN101506368B (zh) 通过可逆的磷酸三酯电荷中和保护基转导运输核酸
EP4058032A1 (en) Compositions for delivery of antisense compounds
JP2009524696A5 (enExample)
CA3007984A1 (en) Polynucleotide constructs having an auxiliary moiety non-bioreversibly linked to an internucleoside phosphate or phosphorothioate
JP2019516686A5 (enExample)
JP2013537404A5 (enExample)
Gogoi et al. Synthesis and RNA binding selectivity of oligonucleotides modified with five-atom thioacetamido nucleic acid backbone structures
TW202325846A (zh) 用於治療周邊髓鞘蛋白22相關疾病的嗎啉代寡聚物
Sood Base modified peptidic nucleic acids: synthesis and crystallographic analysis of intermediates
HK1131188A (en) Transducible delivery of nucleic acids by reversible phosphotriester charge neutralization protecting groups